Losartan Potassium Tablet, Film Coated
Product Images NDC 68788-8189

6 FDA label images from Preferred Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68788-8189). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Losartan Potassium Tab Usp 50mg (68ed9727 987e 4bb6 98b4 B98150bb6404 00)

Losartan Potassium Tab Usp 50mg (68ed9727 987e 4bb6 98b4 B98150bb6404 00)
Losartan Potassium Tablet USP 50 mg film-coated tablet label by Preferred Pharmaceuticals Inc. The label shows the product name, strength, and notes it is generic for Cozaar. Manufacturer details include Solco Healthcare U.S., LLC, Cranbury, NJ. The label includes storage instructions, a barcode, and dosing directions in English and Spanish on a yellow background.*
FDA Label Image

Chemical Structure (Spl Image1 Structure1)

Chemical Structure (Spl Image1 Structure1)
Chemical structure diagram of the active ingredient Losartan potassium, showing its molecular arrangement with labeled atoms and bonds.*
FDA Label Image

Figure 1 (Spl Image2 Figure1)

Figure 1 (Spl Image2 Figure1)
A line graph comparing the percentage of patients with a primary endpoint over 66 study months for Atenolol (dotted line) and Losartan Potassium (solid line). The graph shows a lower percentage for Losartan Potassium, with an adjusted risk reduction of 13% (p=0.021) indicated on the chart.*
FDA Label Image

Figure 2 (Spl Image3 Figure2)

Figure 2 (Spl Image3 Figure2)
A line chart comparing the percentage of patients with fatal or non-fatal stroke over study months for Atenolol and Losartan Potassium. The y-axis shows percentage of patients, and the x-axis shows time in study months up to 66. The chart indicates a 25% adjusted risk reduction with Losartan Potassium compared to Atenolol, with p=0.001.*
FDA Label Image

Figure 3 (Spl Image4 Figure3)

Figure 3 (Spl Image4 Figure3)
A figure titled 'Primary Endpoint Events within Demographic Subgroups' comparing event rates and hazard ratios for Losartan Potassium and Atenolol across various patient demographics and clinical histories. It includes two sections: Primary Composite and Stroke (Fatal/Non-fatal), showing event rates in percentages and hazard ratios with confidence intervals, visually represented with proportional symbols and a forest plot format.*
FDA Label Image

Figure 4 (Spl Image5 Figure4)

Figure 4 (Spl Image5 Figure4)
A line graph displaying the percentage of patients with events over 48 months comparing Losartan Potassium and placebo groups. The solid line represents Losartan Potassium, and the dotted line represents placebo, indicating a risk reduction of 16.1% with a p-value of 0.022.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.